Blog

Red Light Holland Commences Experimental Research on Psilocybin Truffles to Develop Process for Commercial Manufacturing of Natural-Source Active Pharmaceutical Ingredient

Mar 8 • 3 min read

Toronto, Ontario–(Newsfile Corp. – March 8, 2024) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company“), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the…

Alex Atwood is a Psychedelic Integration Coach – Podcast Episode #47

Mar 7 • 2 min read

On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Alex Atwood. Below is how Alex describes himself on LinkedIn. I’ve been an entrepreneur since elementary school when I bought and resold candy and bubble gum from the grocery at a 150% markup. Since then, I have been a founder and…

The UAE Is Exploring the Rollout of Psychedelic Assisted Therapies

Mar 7 • 3 min read

The Energia Foundation and Tabula Rasa Ventures, notable for introducing psychedelic education at Davos in 2022, have been at the forefront of bringing understanding of psychedelic-assisted therapy to the Arabian Gulf. Their efforts over the past 14 months have focused on educating policymakers, sovereign wealth funds, and clinicians in the UAE about the benefits of psychedelic therapies. “Our work here…

The BlueSky Wellness and Lucy Scientific Deal is a No-Go

Mar 7 • 3 min read

In a recent turn of events, Vancouver’s BlueSky Wellness Inc. has decided to abandon its previously anticipated merger with Lucy Scientific Discovery (NASDAQ: LSDI), marking a significant shift in its corporate strategy. BlueSky, a prominent player in the e-commerce hemp sector, has expressed its intention to seek alternative partnerships to fuel its ongoing expansion and…

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

Mar 7 • 7 min read

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder (GAD). The Company also announced that its Phase…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538